Mary Ann Liebert Inc.: Virtual Patients and in Silico Clinical Studies Can Improve Blue Light Treatment for Psoriasis
August 08, 2019
August 08, 2019
NEW ROCHELLE, New York, Aug. 8 -- Mary Ann Liebert Inc. issued the following news release:
A new study supports the use of virtual patients and in silico clinical studies to evaluate the effectiveness of blue light to reduce the symptoms of psoriasis. Researchers also demonstrated that this in silico approach can be used to improve the treatment response of patients with psoriasis to blue light by modifying the settings of the therapeutic protocol, as reported in the study published . . .
A new study supports the use of virtual patients and in silico clinical studies to evaluate the effectiveness of blue light to reduce the symptoms of psoriasis. Researchers also demonstrated that this in silico approach can be used to improve the treatment response of patients with psoriasis to blue light by modifying the settings of the therapeutic protocol, as reported in the study published . . .